Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Patients who participated in the previous trial 28130, who were eligible, were entered into
this trial. Patients who were randomized to placebo in the previous trial 28130 continued on
placebo while patients who were randomized to Org 34517 (SCH 900636), regardless of dose,
were titrated to 900 mg Org 34517. Patients in this trial took their study medication for 2
weeks in order to study the safety and tolerability of Org 34517.